Cipher Pharmaceuticals (FRA:PHE) Net Interest Margin (Bank Only) %


FRA:PHE Cipher Pharmaceuticals Inc FRA:PHE
85 GF Score
Price €10.40
GF Value €10.50
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:PHE
85GF Score
Cipher Pharmaceuticals Inc FRA:PHE
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cipher Pharmaceuticals (FRA:PHE) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of €10.40 is trading 1% below its estimated GF Value™ of €10.50. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:PHE:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €10.50 vs. price of €10.40 (1% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the FRA:PHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Other Exchanges CPHRF:USACPH:Canada
Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
85GF Score

Get the complete analysis for FRA:PHE

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.40
Price
€10.50
GF Value